Evidence and experience with onabotulinumtoxinA in chronic migraine : Recommendations for daily clinical practice Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria
Gago-Veiga, Ana Beatriz ![ORCID Identifier](/img/uab/orcid.ico)
(Instituto de Investigación Hospital Universitario de la Princesa)
Santos Lasaosa, Sonia ![ORCID Identifier](/img/uab/orcid.ico)
(Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Cuadrado, María Luz ![ORCID Identifier](/img/uab/orcid.ico)
(Universidad Complutense de Madrid. Departamento de Medicina)
Guerrero, Ángel Luis (Hospital Clínico Universitario de Valladolid)
Irimia, Pablo ![ORCID Identifier](/img/uab/orcid.ico)
(Clínica Universidad de Navarra)
Lainez Andres, Jose Miguel ![ORCID Identifier](/img/uab/orcid.ico)
(Hospital Clínic Universitari (València))
Leira, Rogelio
(Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Pascual Gómez, Julio
(Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria))
Sanchez del Río, Margarita (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Viguera, Javier
(Hospital Universitari Vall d'Hebron)
Pozo-Rosich, Patricia
(Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona
Date: |
2019 |
Abstract: |
OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ![Creative Commons](/img/licenses/by-nc-nd.ico) |
Language: |
Castellà |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Consenso ;
Migraña crónica ;
OnabotulinumtoxinA ;
Toxina botulínica A ;
Tratamiento preventivo ;
Recomendaciones |
Published in: |
Neurología, Vol. 34 Núm. 6 (julio 2019) , p. 408-417, ISSN 1578-1968 |
DOI: 10.1016/j.nrl.2017.09.008
PMID: 29169810
The record appears in these collections:
Articles >
Research articlesArticles >
Published articles
Record created 2020-06-03, last modified 2024-06-11